Resultados de la búsqueda 231-240 of 2732 for Reabsorption
Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...
Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with ...
The primary objective of this proposal is to develop a Thoracic Specimen Registry at Mayo Clinic. The purpose of the registry will be to support ongoing ...
A total of 8,000 patients presenting to CPSs with acute-onset AIS, ICH or aSAH and no history of dementia will be enrolled within 6 weeks of stroke onset. All ...
Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...
Scottsdale/Phoenix, Ariz. This phase II trial tests whether an exercise intervention works to improve cognitive function in breast cancer survivors. Many breast ...
Rochester, Minn. The purpose of this study is evaluate the outcomes and complications in patients who underwent a rotator cuff repair. Benevolent Tumor Tissue ...
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival ...
The performance characteristics of the ddPCR assay for the detection of ctDNA mutation in uveal melanoma patients will be assessed by comparing the mutation ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?